Back to Newsroom

Global Genomics Group (G3) and Illumina to Partner on Cardiovascular Genomics

RICHMOND, Va., and SAN DIEGO, Sept. 25, 2013 – Global Genomics Group (G3) and Illumina, Inc. (NASDAQ:ILMN) today announced that they have entered into a partnership to investigate novel biomarkers and biological pathways involved in the development and diagnosis of cardiovascular diseases. Under the terms of the agreement, Illumina will conduct whole genome sequencing (WGS) in the GLOBAL (Genetic LOci and the Burden of Atherosclerotic Lesions) clinical study.